| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on April 28, 2004
Accepted on October 20, 2004
Departments of Cellular and Molecular Physiology (V.N.D., J.K.W., K.L.H., S.R.K., J.M.M.) and Obstetrics and Gynecology (R.S.L., J.M.M.), Pennsylvania State University College of Medicine, Hershey, PA 17033, the Department of Diabetes and Metabolism (T.A., M.F.), Graduate School of Medicine, University of Tokyo, Bunkyo-ku, Tokyo 113-8655, Japan, and the Center for Research on Reproduction and Women's Health (J.F.S.), University of Pennsylvania, Philadelphia, PA 19104
* To whom correspondence should be addressed. E-mail: jmcallister{at}psu.edu.
We have investigated the involvement of the mitogen activated protein kinase (MAPK) signaling pathway in increased androgen biosynthesis and CYP17 gene expression in women with polycystic ovary syndrome (PCOS). A comparison of mitogen activated protein kinase kinase (MEK1/2) and extracellular signal-related kinase (ERK1/2) phosphorylation in propagated normal and PCOS theca cells, revealed that MEK1/2 phosphorylation was decreased >70%, and ERK1/2 phosphorylation was reduced 50% in PCOS cells as compared with normal cells. Infection with dominant negative MEK1 (DN-MEK1) increased CYP17 mRNA and DHEA abundance, whereas constitutively active MEK1 (CA-MEK1) inhibited DHEA production and CYP17 mRNA abundance. Similarly, the MEK inhibitor, PD98059 (PD), increased CYP17 mRNA accumulation and CYP17 promoter activity to levels observed in PCOS cells. Remarkably, in theca cells maintained in the complete absence of insulin, ERK1/2 phosphorylation was decreased in PCOS theca cells as compared with normal theca cells, and CYP17 mRNA and DHEA synthesis were increased in PCOS theca cells. These studies demonstrate that in PCOS cells reduced levels of activated MEK1/2 and ERK1/2 are correlated with increased androgen production, irrespective of the insulin concentration. These findings implicate alterations in the MAPK pathway in the pathogenesis of excessive ovarian androgen production in PCOS.
This article has been cited by other articles:
![]() |
M. K. Tee, Q. Dong, and W. L. Miller Pathways Leading to Phosphorylation of P450c17 and to the Posttranslational Regulation of Androgen Biosynthesis Endocrinology, May 1, 2008; 149(5): 2667 - 2677. [Abstract] [Full Text] [PDF] |
||||
![]() |
G.-S. Hwang, S.-W. Wang, W.-M. Tseng, C.-H. Yu, and P. S. Wang Effect of hypoxia on the release of vascular endothelial growth factor and testosterone in mouse TM3 Leydig cells Am J Physiol Endocrinol Metab, June 1, 2007; 292(6): E1763 - E1769. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Kempna, G. Hofer, P. E. Mullis, and C. E. Fluck Pioglitazone Inhibits Androgen Production in NCI-H295R Cells by Regulating Gene Expression of CYP17 and HSD3B2 Mol. Pharmacol., March 1, 2007; 71(3): 787 - 798. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Taniguchi, J. F. Couse, K. F. Rodriguez, J. M. A. Emmen, D. Poirier, and K. S. Korach Estrogen receptor-{alpha} mediates an intraovarian negative feedback loop on thecal cell steroidogenesis via modulation of Cyp17a1 (cytochrome P450, steroid 17{alpha}-hydroxylase/17,20 lyase) expression FASEB J, February 1, 2007; 21(2): 586 - 595. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H M Lima, L. C Souza, L. C Caperuto, E. Bevilacqua, A. L Gasparetti, R. Zanuto, M. J A Saad, and C. R O Carvalho Up-regulation of the phosphatidylinositol 3-kinase/protein kinase B pathway in the ovary of rats by chronic treatment with hCG and insulin. J. Endocrinol., August 1, 2006; 190(2): 451 - 459. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Corbould, H. Zhao, S. Mirzoeva, F. Aird, and A. Dunaif Enhanced Mitogenic Signaling in Skeletal Muscle of Women With Polycystic Ovary Syndrome Diabetes, March 1, 2006; 55(3): 751 - 759. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Zhou, I. M. Bird, D. A. Dumesic, and D. H. Abbott Adrenal Hyperandrogenism Is Induced by Fetal Androgen Excess in a Rhesus Monkey Model of Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6630 - 6637. [Abstract] [Full Text] [PDF] |
||||
![]() |
D.H. Abbott, D.K. Barnett, C.M. Bruns, and D.A. Dumesic Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome? Hum. Reprod. Update, July 1, 2005; 11(4): 357 - 374. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |